In This Issue:

Investor Q&A; Key Regulatory Issues for Strategic Life Sciences Partnerships in China; Compulsory Patent Licensing in China; and New Developments on the “Patentable Subject Matter” Requirement of U.S. Patent Law.

Excerpt from Investor Q&A -

Dr. Dan Zhang has more than ten years of drug development experience. He is the Chief Executive Officer of Fountain Medical Development, a full-service clinical CRO company based in South East Asia and China. Previously, Dr. Zhang was the head of clinical development and global safety assessment at Sigma-Tau Research Inc., a Vice President at the Quintiles Transnational Corp., and the Chairman of the Board at Quintiles Medical Development (Shanghai) Company Ltd.